Drug Type Synthetic peptide |
Synonyms- |
Target |
Action agonists |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (23 Dec 2024), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | United States | 23 Dec 2024 |
Not Applicable | - | - | whhtqchexs(vnzdqryfzi): OR = 1.76 (95% CI, 1.56 - 1.99) View more | Positive | 02 Oct 2018 | ||